Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Daniela Fenili"'
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e24032 (2011)
Inositol stereoisomers, myo- and scyllo-inositol, are known to enter the brain and are significantly elevated following oral administration. Elevations in brain inositol levels occur across a concentration gradient as a result of active transport fro
Externí odkaz:
https://doaj.org/article/811ffb7f8f604b359abab40692259da7
Publikováno v:
FEBS Journal. 275:1663-1674
Amyloid-beta (Abeta) aggregation and amyloid formation are key pathological features of Alzheimer's disease, and are considered to be two of the major contributing factors to neurodegeneration and dementia. Identification of small molecule inhibitors
Autor:
Daniela Fenili, JoAnne McLaurin
Publikováno v:
Current Drug Target -CNS & Neurological Disorders. 4:553-567
Alzheimer's disease (AD) is a debilitating disease that affects many people. In order to reduce the number of people diagnosed with this disease, drug strategies need to be implemented that target early steps in disease pathogenesis. Elevated cholest
Publikováno v:
Future Neurology. 5:353-355
The Keystone Symposium on Alzheimer’s disease (AD), held in Copper Mountain, CO, USA, provided an opportunity for research scientists and industry experts in the field of AD and related disciplines to meet and discuss the future of AD research. Thi
Publikováno v:
Alzheimer's & Dementia. 8
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e24032 (2011)
PLoS ONE
PLoS ONE
Inositol stereoisomers, myo- and scyllo-inositol, are known to enter the brain and are significantly elevated following oral administration. Elevations in brain inositol levels occur across a concentration gradient as a result of active transport fro
Publikováno v:
Current Alzheimer research. 9(8)
The role of microglia in β-amyloid (Aβ) deposition or clearance in the Alzheimer's disease (AD) brain remains unclear. Previous in vivo studies have focused primarily on the association of microglia with Aβ-positive parenchymal plaques, but have g
One challenge for designing drugs to treat Alzheimer's diseases is to identify compounds that are effective at binding to and preventing protein aggregation not only in vitro but also in vivo. This requires blood-brain barrier permeability at levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a0f0cd44e40e87fd7816eaefe7baa16
https://doi.org/10.1039/9781849731065-00094
https://doi.org/10.1039/9781849731065-00094
Publikováno v:
Alzheimer's & Dementia. 5
Autor:
JoAnne McLaurin, Daniela Fenili
Publikováno v:
Alzheimer's & Dementia. 4